- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06513156
Continuità assistenziale nei pazienti ospedalizzati con disturbo da uso di oppioidi e complicanze infettive derivanti dall’uso di farmaci (CHOICE-STAR)
La continuità assistenziale nei pazienti ospedalizzati con disturbo da uso di oppioidi e complicanze infettive legate all'uso di farmaci - NavSTAR, Treatment as Usual, Clinica integrata per la dipendenza/identificazione per prevenire la riammissione correlata all'infezione
This is a two-group randomized controlled trial conducted at five hospitals across the U.S. designed to test the effectiveness of an Integrated infectious diseases/Substance Use Disorder outpatient clinic (IC) compared to treatment as usual aimed at reducing infection related readmissions and improving health outcomes in people hospitalized with an infection related to injecting opioids or stimulants.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This is a phase III two arm randomized controlled trial to determine the impact and Integrated infectious diseases (ID) and Substance Use Disorder outpatient clinic (IC) compared to treatment as usual on infection related rehospitalization in individuals hospitalized with infections due to injecting opioids or Stimulants, in the 6 month time period after discharge. This study includes both cost effectiveness and implementation outcomes.
(1) IC will provide facilitated linkage to a clinic providing medical treatment aimed at treating substance use disorder (SUD), resolving the index infection, treating existing ID complications of OUD (HIV, HCV, wounds) and preventing subsequent infections by providing accessible care for infectious diseases and medication for OUD (MOUD) treatment that is integrated into a single appointment and co-located at a single site (either in person or via telemedicine) for a minimum of monthly appointments over a 6 month time period. A feature of the IC will be weekly care coordination meetings between the ID and MOUD providers.
The study will recruit patients during hospitalization for an infection due to injecting opioids or stimulants at four hospital systems (five hospitals) and randomly assign approximately 304 inpatients in 1:1 ratio to IC vs TAU.
Participants will be followed for 12 months.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Rachel Silk
- Numero di telefono: 301-326-7652
- Email: rsilk@ihv.umaryland.edu
Luoghi di studio
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20052
- Reclutamento
- George Washington University
-
Sub-investigatore:
- Irene Kuo, MD
-
Contatto:
- Jill Catalanotti, MD
- Email: jcatalanotti@mfa.gwu.edu
-
Investigatore principale:
- Jill Catalanotti, MD
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Reclutamento
- Emory University
-
Investigatore principale:
- Joseph Carpenter, MD
-
Contatto:
- Joseph Carpenter, MD
- Email: joseph.edward.carpenter@emory.edu
-
Sub-investigatore:
- Alina Steck, MD
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21201
- Reclutamento
- University of Maryland Baltimore
-
Sub-investigatore:
- Edward Traver, MD
-
Investigatore principale:
- Elana Rosenthal, MD
-
Sub-investigatore:
- Sarah Kattakuzhy, MD
-
Contatto:
- Rachel Silk
- Numero di telefono: 3013267652
- Email: rsilk@ihv.umaryland.edu
-
-
West Virginia
-
Morgantown, West Virginia, Stati Uniti, 26506
- Reclutamento
- West Virginia University
-
Contatto:
- Rebecca Reece, MD
- Email: rreece@hsc.wvu.edu
-
Investigatore principale:
- Rebecca Reece, MD
-
Sub-investigatore:
- Clinton Cooper, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age ≥ 18 years
- Admitted to study hospital (defined as hospitalized with a primary team that is not Emergency Medicine)
- Injection opioid or stimulant use in past 90 days - per patient self-report
- Active suspected or confirmed qualifying infection (see list) at time of admission.
Qualifying infections:
- Non-vertebral osteomyelitis
- Vertebral osteomyelitis or discitis
- Epidural, subdural, or extradural abscess
- Intracranial or intraspinal abscess
- Native joint septic arthritis
- Prosthetic joint septic arthritis
- Blood stream infection (bacterial or fungal)
- Native valve Endocarditis
- Prosthetic valve endocarditis
- Cardiac Implantable electronic device infection
- Infectious pseudoaneurysm and aneurysm
- Infected vascular graft
- Septic venous thrombosis
- Skin and Soft tissue infection (cellulitis, skin abscess, necrotizing fasciitis)
- Infected skin ulcer
- Orthopedic hardware infection
- Muscle abscess/myositis
- Central nervous system infection (bacterial or fungal)
- Bacterial or fungal ophthalmologic infection
- Other abscess
- Pulmonary septic emboli
- Other acute bacterial or fungal infection deemed appropriate by site study team
Exclusion Criteria:
-
1. Infection due to a cause other than injection drug use, per determination of a site PI.
2. Inability to provide consent due to circumstance (e.g., sedated, intubated), language, or cognitive impairment.
3. Unwilling to provide informed consent 4. Unable to receive potential interventions due to geography 5. On comfort measures or planned for discharge to hospice care 6. Incarcerated at the time of hospitalization 7. Other criteria at the discretion of the site investigator
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Nessun intervento: Treatment As Usual
Will receive treatment for infection and opioid or stimulant use disorder per the usual care at each hospital |
|
|
Sperimentale: Integrated Infectious Diseases and Substance Use Disorder Clinic (IC)
The Integrated ID/SUD Clinic will provide facilitated linkage to a clinic providing medical treatment aimed at treating SUD, resolving the sentinel infection, treating existing ID complications of OUD/stimulants (HIV, HCV, wounds) and preventing subsequent infections by providing accessible care for infectious diseases and MOUD treatment that is integrated into a single appointment and co-located at a single site (either in person or via telemedicine) for a minimum of monthly appointments over a 6 month time period. A feature of the IC will be weekly care coordination meetings between the ID and SUD providers. The dual goals of the IC intervention are to 1) to facilitate accessibility to ID and OUD care and 2) to ensure care coordination between outpatient ID and SUD providers. |
Integrated medication for opioid/stimulant use disorder and infectious disease care provided into single appointment either in person or via telemedicine with a minimum of monthly appointments for 6 months. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Infection Rehospitalization
Lasso di tempo: 6 months after discharge for index hospitalization
|
New hospitalization due to infection following discharge for index hospitalization |
6 months after discharge for index hospitalization
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Time to first infection related readmission
Lasso di tempo: 12 months after discharge for index hospitalization
|
Time to first infection related readmission |
12 months after discharge for index hospitalization
|
|
Reason for infection related readmission
Lasso di tempo: 12 months after discharge for index hospitalization
|
Reason for infection related readmission (persistent index infection, new IDU associated infection, other infection) |
12 months after discharge for index hospitalization
|
|
Hospital services utilization
Lasso di tempo: 12 months after discharge for index hospitalization
|
ED visits (Binary, count, time to first ED visit, cause) and Readmission, all cause (binary, count, time to first readmission, cause) |
12 months after discharge for index hospitalization
|
|
Mortality
Lasso di tempo: 12 months after discharge for index hospitalization
|
Death (Binary, time to death, cause of death) |
12 months after discharge for index hospitalization
|
|
Index infection
Lasso di tempo: 3 months after discharge for index hospitalization
|
Completion of antibiotics (binary, reason for incomplete antibiotics); Resolution of index infection (binary) Skilled Nursing Facility (SNF) Admitted to SNF (binary) Discharge type from SNF (planned, PDD, dead, transfer) |
3 months after discharge for index hospitalization
|
|
Other Infections
Lasso di tempo: 12 months after discharge for index hospitalization
|
HCV Active HCV (binary) Clinical evaluation (binary) DAA prescribed (binary) DAA initiated (binary) SVR achieved (binary) HIV Diagnosis status (binary) HIV VL undetectable (binary) ART Taking (binary) Type (pills vs injections) Adherence (# missed doses in last 30 days) PrEP Eligible (CDC Criteria, binary, indication) Offered by healthcare provider (binary) Taking (binary) Type (pills vs injections) Adherence (# missed doses in last 30 days) |
12 months after discharge for index hospitalization
|
|
Skin and soft tissue wounds
Lasso di tempo: 12 months after discharge for index hospitalization
|
Present (binary) Number (count) Per wound Size Location on body Duration (continuous) |
12 months after discharge for index hospitalization
|
|
New infections not requiring hospitalization
Lasso di tempo: 12 months after discharge for index hospitalization
|
|
12 months after discharge for index hospitalization
|
|
Outpatient linkage and retention
Lasso di tempo: 12 months after discharge for index hospitalization
|
|
12 months after discharge for index hospitalization
|
|
Medication for Opioid Use (MOUD)
Lasso di tempo: 12 months after discharge for index hospitalization
|
|
12 months after discharge for index hospitalization
|
|
Medication for stimulant use (MStUD)
Lasso di tempo: 12 months after discharge for index hospitalization
|
|
12 months after discharge for index hospitalization
|
|
Substance Use-Opioid
Lasso di tempo: 12 months after discharge for index hospitalization
|
Ongoing opioid (binary, mode)
|
12 months after discharge for index hospitalization
|
|
Substance Use - Stimulant
Lasso di tempo: 12 months after discharge for index hospitalization
|
Ongoing stimulant use (binary, mode)
|
12 months after discharge for index hospitalization
|
|
Cost Effectiveness
Lasso di tempo: 12 months after discharge for index hospitalization
|
• ICER for quality adjusted life years (QALYs); opioid-free years (OfYs); and infection-free years (IfYs) gained |
12 months after discharge for index hospitalization
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Elana Rosenthal, MD, University of Maryland, Baltimore
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- HP-00111318
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .